SG11201408750VA - NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS - Google Patents
NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORSInfo
- Publication number
- SG11201408750VA SG11201408750VA SG11201408750VA SG11201408750VA SG11201408750VA SG 11201408750V A SG11201408750V A SG 11201408750VA SG 11201408750V A SG11201408750V A SG 11201408750VA SG 11201408750V A SG11201408750V A SG 11201408750VA SG 11201408750V A SG11201408750V A SG 11201408750VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- bld29
- disheng
- daxing
- bpu
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012077924 | 2012-06-29 | ||
PCT/CN2013/078592 WO2014000713A1 (en) | 2012-06-29 | 2013-07-01 | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201408750VA true SG11201408750VA (en) | 2015-01-29 |
Family
ID=49782283
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201408750VA SG11201408750VA (en) | 2012-06-29 | 2013-07-01 | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS |
Country Status (15)
Country | Link |
---|---|
US (1) | US9617257B2 (es) |
EP (1) | EP2867223B1 (es) |
JP (1) | JP6059342B2 (es) |
KR (3) | KR101726522B1 (es) |
AU (1) | AU2013283993B2 (es) |
BR (1) | BR112014032745B1 (es) |
CA (1) | CA2878049C (es) |
ES (1) | ES2698511T3 (es) |
HK (1) | HK1207642A1 (es) |
IN (1) | IN2015DN00372A (es) |
RU (1) | RU2619130C2 (es) |
SG (1) | SG11201408750VA (es) |
TW (1) | TWI520962B (es) |
WO (1) | WO2014000713A1 (es) |
ZA (1) | ZA201500344B (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106279147A (zh) | 2015-05-21 | 2017-01-04 | 中国科学院上海药物研究所 | 一种吡啶并氮杂环化合物及其制备方法和用途 |
CN108026070B (zh) * | 2015-07-20 | 2021-01-01 | 贝达药业股份有限公司 | 新型稠合吡啶衍生物的马来酸盐晶型及其用途 |
CN106924260B (zh) * | 2015-12-31 | 2018-05-25 | 北京浦润奥生物科技有限责任公司 | 化合物在制备用于治疗脑胶质瘤的药物中的用途 |
WO2017136727A2 (en) | 2016-02-05 | 2017-08-10 | Denali Therapeutics Inc. | Compounds, compositions and methods |
JP7208137B2 (ja) | 2016-12-09 | 2023-01-18 | デナリ セラピューティクス インコーポレイテッド | 化合物、組成物および方法 |
JP2021506735A (ja) * | 2017-05-26 | 2021-02-22 | イクノス サイエンシズ エスエー | 新規map4k1阻害剤 |
JP7131837B2 (ja) * | 2017-06-19 | 2022-09-06 | アビスコ セラピューティクス カンパニー リミテッド | Csf-1r阻害活性を有するアザアリール誘導体、その製造方法および応用 |
CN109988108B (zh) * | 2017-12-29 | 2022-04-29 | 江苏豪森药业集团有限公司 | 一种卡博替尼的制备方法 |
JP2022513215A (ja) * | 2018-12-14 | 2022-02-07 | ベータ・ファーマ・インコーポレイテッド | C-met阻害剤としての有機リン置換化合物およびその治療用途 |
BR112021018168B1 (pt) | 2019-03-21 | 2023-11-28 | Onxeo | Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer |
AU2020378630A1 (en) | 2019-11-08 | 2022-05-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
TWI812301B (zh) * | 2021-06-24 | 2023-08-11 | 南韓商Lg化學股份有限公司 | 作為ron抑制劑之新穎尿素衍生物化合物 |
TW202334164A (zh) | 2022-01-12 | 2023-09-01 | 美商戴納立製藥公司 | (S)-5-苄基-N-(5-甲基-4-側氧基-2,3,4,5-四氫吡啶並[3,2-b][1,4]氧氮呯-3-基)-4H-1,2,4-三唑-3-甲醯胺的晶型 |
EP4289427A1 (en) * | 2022-06-10 | 2023-12-13 | Anagenesis Biotechnologies | Dihydro[1,8]naphthyridin-7-one and pyrido[3,2-b][1,4]oxazin-3-one for use in treating cancer, and metastases in particular. |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005005389A2 (en) | 2003-07-07 | 2005-01-20 | Merck Patent Gmbh | Malonamide derivatives |
DE10357510A1 (de) * | 2003-12-09 | 2005-07-07 | Bayer Healthcare Ag | Heteroarylsubstituierte Benzole |
US7173031B2 (en) * | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
EP1773826A4 (en) * | 2004-07-02 | 2009-06-03 | Exelixis Inc | MODULATORS OF C-MET AND THEIR METHOD OF USE |
ES2438017T3 (es) * | 2004-07-30 | 2014-01-15 | Methylgene Inc. | Inhibidores de la señalización del receptor del VEGF y del receptor del HGF |
JP2008521900A (ja) * | 2004-11-30 | 2008-06-26 | アムジエン・インコーポレーテツド | キノリン及びキナゾリン類似体並びにがん治療のための医薬としてのその使用 |
JO2787B1 (en) * | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
JP5275792B2 (ja) | 2005-05-20 | 2013-08-28 | メチルジーン インコーポレイテッド | Vegfレセプターおよびhgfレセプターシグナル伝達の阻害剤 |
WO2008049855A2 (en) * | 2006-10-27 | 2008-05-02 | Glaxo Group Limited | 7-azaindole derivatives as c-met kinase inhibitors |
US7960567B2 (en) | 2007-05-02 | 2011-06-14 | Amgen Inc. | Compounds and methods useful for treating asthma and allergic inflammation |
KR100961410B1 (ko) * | 2008-10-14 | 2010-06-09 | (주)네오팜 | 단백질 키나제 억제제로서 헤테로사이클릭 화합물 |
WO2010045095A1 (en) * | 2008-10-14 | 2010-04-22 | Ning Xi | Compounds and methods of use |
CN102086211B (zh) * | 2009-12-08 | 2013-09-11 | 广东东阳光药业有限公司 | 作为蛋白激酶抑制剂的芳杂环化合物 |
WO2012006960A1 (en) * | 2010-07-14 | 2012-01-19 | Zhejiang Beta Pharma Inc. | NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS |
-
2013
- 2013-06-29 TW TW102123415A patent/TWI520962B/zh not_active IP Right Cessation
- 2013-07-01 KR KR1020157002238A patent/KR101726522B1/ko active IP Right Grant
- 2013-07-01 CA CA2878049A patent/CA2878049C/en not_active Expired - Fee Related
- 2013-07-01 BR BR112014032745-9A patent/BR112014032745B1/pt not_active IP Right Cessation
- 2013-07-01 EP EP13809182.2A patent/EP2867223B1/en not_active Not-in-force
- 2013-07-01 KR KR1020177003331A patent/KR101770545B1/ko active IP Right Grant
- 2013-07-01 US US14/411,515 patent/US9617257B2/en active Active
- 2013-07-01 AU AU2013283993A patent/AU2013283993B2/en not_active Ceased
- 2013-07-01 ES ES13809182T patent/ES2698511T3/es active Active
- 2013-07-01 IN IN372DEN2015 patent/IN2015DN00372A/en unknown
- 2013-07-01 WO PCT/CN2013/078592 patent/WO2014000713A1/en active Application Filing
- 2013-07-01 RU RU2015102057A patent/RU2619130C2/ru active
- 2013-07-01 KR KR1020177003335A patent/KR101726555B1/ko active IP Right Grant
- 2013-07-01 JP JP2015518816A patent/JP6059342B2/ja not_active Expired - Fee Related
- 2013-07-01 SG SG11201408750VA patent/SG11201408750VA/en unknown
-
2015
- 2015-01-16 ZA ZA2015/00344A patent/ZA201500344B/en unknown
- 2015-08-27 HK HK15108314.5A patent/HK1207642A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR20170017014A (ko) | 2017-02-14 |
KR20150031320A (ko) | 2015-03-23 |
EP2867223B1 (en) | 2018-09-05 |
JP2015521634A (ja) | 2015-07-30 |
ES2698511T3 (es) | 2019-02-05 |
EP2867223A4 (en) | 2016-01-06 |
AU2013283993A1 (en) | 2015-02-05 |
CA2878049A1 (en) | 2014-01-03 |
TW201418254A (zh) | 2014-05-16 |
TWI520962B (zh) | 2016-02-11 |
JP6059342B2 (ja) | 2017-01-11 |
US20150315210A1 (en) | 2015-11-05 |
CA2878049C (en) | 2016-12-13 |
KR101726555B1 (ko) | 2017-04-12 |
EP2867223A1 (en) | 2015-05-06 |
US9617257B2 (en) | 2017-04-11 |
WO2014000713A1 (en) | 2014-01-03 |
BR112014032745A2 (pt) | 2017-06-27 |
KR101770545B1 (ko) | 2017-08-22 |
KR20170017015A (ko) | 2017-02-14 |
RU2015102057A (ru) | 2016-08-20 |
IN2015DN00372A (es) | 2015-06-12 |
AU2013283993B2 (en) | 2016-07-07 |
RU2619130C2 (ru) | 2017-05-12 |
BR112014032745B1 (pt) | 2022-01-04 |
HK1207642A1 (en) | 2016-02-05 |
ZA201500344B (en) | 2016-08-31 |
KR101726522B1 (ko) | 2017-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201408750VA (en) | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | |
SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
SG11201908820VA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
SG11201408821SA (en) | Selective pi3k delta inhibitors | |
SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
SG11201408237YA (en) | Compound as wnt signaling inhibitor, composition, and use thereof | |
SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
SG11201900163PA (en) | Macrocycle kinase inhibitors | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201407417VA (en) | Encoding and reconstruction of residual data based on support information | |
SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
SG11201407372UA (en) | Nampt inhibitors | |
SG11201908602UA (en) | Combination therapy for the treatment of solid and hematological cancers | |
SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
SG11201407988UA (en) | Process for improved opioid synthesis | |
SG11201909807TA (en) | Methods of manufacturing of niraparib | |
SG11201408119PA (en) | Systems and methods for data center cooling and water desalination | |
SG11201908114UA (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
SG11201407184PA (en) | Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals | |
SG11201408037SA (en) | Humanized anti-trka antibodies with amino acid substitutions | |
SG11201407591PA (en) | Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof | |
SG11201901172QA (en) | A method for manufacturing a fuel component |